



Journal of Hospital Pharmacy
An Official Publication of Bureau for Health & Education Status Upliftment
 (Constitutionally Entitled as Health-Education, Bureau)

Observational study on management of breast cancer

Dr. Shubam Babu Guptha, Pothuganti Prasanna, Kadira Sri Charan,
 Avula Madhu Sudhan Reddy, Golakoti Durga Sai Krishna Vinay

Corresponding Author address -Department of Pharmacy Practice, Assistant professor & Pharm D, Malla Reddy Institute of Pharmaceutical Sciences, Maisammaguda, Secunderabad, Telangana, India-500014

Author Address 2,3, 4- Pharm D, Department of Pharmacy Practice. Malla Reddy Institute of Pharmaceutical Sciences, Maisammaguda, Secunderabad, Telangana, India- 500014


Corresponding Author: Dr. Shubam babu guptha

Email Id: serviceheb@gmail.com

ABSTRACT

Background: Breast cancer is categorized into stages based on the extent of their growth and the presence or extent of their metastasis. The severity of the cancer determines how it is treated. Chemotherapy, radiation, hormone therapy, and surgery are all potential components. **Objective:** To observe the prescribing patterns and management of breast cancer and to monitor the effect of adjuvant therapy in treatment of breast cancer and to observe the side effects associated with treatment regimen **Method:** It was a prospective observational study of 200 people with breast cancer. From August 2022 to January 2023, information was gathered using a standardized data collection form and analyzed statistically. **Result:** The study findings suggest that the prevalence of benign cancer, which accounted for approximately 79% of cases in female patients aged 46–55, was more associated with the combination treatment approach for cancer management with a higher therapeutic outcome and a lower ADR profile. The study emphasizes that the chances of re-occurrences play a major role in the mortality and morbidity of the patient. In our study, the occurrence rate was found to be around 31%. **Conclusion:** Advances in medical science and technology. By continuing to develop new targeted therapies based on a better understanding of tumor heterogeneity and molecular profiles, I emphasize opting for advanced treatment regimes in order to improve therapeutic efficacy and optimize the ADR profile, where a clinical pharmacist can play a major role in the management of ADRs, thereby increasing the quality of life of patients.

Keywords: Malignant, metastasis, adjuvant-therapy, mortality, heterogeneity.

Access this Article Online	Quick Response Code 
Website: http://www.journalofhospitalpharmacy.in	
Received on 13/04/2023	
Accepted on 22/04/2023 © HEB All rights reserved	